Immunic announces public offering of warrants and posts extended phase 2 CALLIPER data

IMMUNIC, INC.

Commenced underwritten public offering of pre-funded warrants and Series A (expire Dec 31, 2025) and Series B (5-year) warrants.
Leerink Partners sole bookrunner; proceeds to fund clinical trials and general corporate purposes.
Posted updated corporate presentation with extended data from phase 2 CALLIPER trial of vidofludimus calcium in progressive MS.
Offering is subject to market conditions; no assurance of completion or final terms.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.